Get the Stockscreener App
2.34
2.09%
-0.05
Creative Medical Technology Holdings Inc stock is traded at $2.34, with a volume of 61,597.
It is down -2.09% in the last 24 hours and up +1.74% over the past month.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
See More
Previous Close:
$2.39
Open:
$2.31
24h Volume:
61,597
Relative Volume:
1.24
Market Cap:
$8.65M
Revenue:
$6,000
Net Income/Loss:
$-6.00M
P/E Ratio:
-1.0198
EPS:
-2.2945
Net Cash Flow:
$-5.86M
1W Performance:
+6.85%
1M Performance:
+1.74%
6M Performance:
-12.36%
1Y Performance:
+15.84%
1-Day Range:
$2.31
$2.39
1-Week Range:
$2.19
$2.395
52-Week Range:
$1.504
$6.25
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Name
Creative Medical Technology Holdings Inc
Sector
Industry
Phone
480-399-2822
Address
211 E. OSBORN RD., PHOENIX
Compare CELZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
2.34 | 8.84M | 6,000 | -6.00M | -5.86M | -2.2945 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Creative Medical Technology Holdings Inc Stock (CELZ) Latest News
Creo Medical shares surge 27% on proposed sale of remaining European stake - Yahoo Finance
Creative Medical Technology Holdings, Inc.Common Stock (NQ: CELZ - FinancialContent
Accel Entertainment (ACEL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Xtant Medical Q1 2026 Results: Revenue Guidance Raised, Balance Sheet Strengthened, Exclusive HEMOBLAST® Bellows Distribution Secured 12 - Minichart
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control - Yahoo Finance
Incannex Healthcare Wins MedTech Breakthrough Award for Innovative Obstructive Sleep Apnea Drug IHL-42X - Minichart
Creative Global Technology Holdings And 2 Other Promising Penny Stocks - Yahoo Finance
United States shares higher at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com
CELZ (CreativeMed) EPS beats estimates but shares fall nearly 3% despite narrower losses.AI Stock Signals - Newser
Creative Medical Technology Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Creative Medical Technology (NASDAQ: CELZ) posts Q1 2026 loss, details cash use - Stock Titan
How CreativeMed (CELZ) prepares for market disruptions | Q3 2025: Earnings Beat EstimatesTrend Analysis - newser.com
Creative Medical Technology Holdings Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion - Yahoo Finance
Roth MKM Maintains Creative Medical Technology(CELZ.US) With Buy Rating, Maintains Target Price $20 - Moomoo
BZLEY Should I Buy - Intellectia AI
Creative Medical (CELZ) Reports Encouraging Pilot Study Results for Ultrasome Therapy - GuruFocus
Creative Medical (CELZ) Reports Promising Osteoarthritis Therapy Results - GuruFocus
BY Technical Analysis & Price Forecast - Intellectia AI
Creative Medical reports positive pilot study results for Ultrasome - Investing.com UK
Creative Medical reports positive pilot study results for Ultrasome By Investing.com - Investing.com Australia
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies - The Manila Times
Park Place Technologies Partners with Professional Athlete Genie Bouchard as 'Genie from IT” in New TV Commercial - The Manila Times
Uncertainty Around AI’s Impact on Careers Clouds Students’ College Decisions - The Manila Times
Cell-free knee arthritis therapy posts 93% response in pilot study - Stock Titan
JXHLY Forecast — Price Prediction for 2026. Should I Buy JXHLY? - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NPSKY Technical Analysis & Stock Price Forecast - Intellectia AI
BHPCD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Iran Hormuz Strait Crisis: Oil Market Impact & Energy Investment Strategy 2026 - Intellectia AI
NAII Technical Analysis & Price Forecast - Intellectia AI
MITT Technical Analysis & Price Forecast - Intellectia AI
RWAY Technical Analysis & Price Forecast - Intellectia AI
Creative Medical Technology Holdings, Inc. 2025 Annual Report: Executive Summary, Compensation, and Compliance Disclosures - Minichart
IBEX Technical Analysis & Price Forecast - Intellectia AI
TOVXPrice, Charts & Blockchain Insights - Intellectia AI
Creative Medical (NASDAQ: CELZ) details 2025 pay, ownership and deals - Stock Titan
VMC Technical Analysis & Price Forecast - Intellectia AI
GE Vernova Stock Analysis 2026: Q1 Earnings Beat Signals Powerhouse Momentum - Intellectia AI
HDSN Technical Analysis & Price Forecast - Intellectia AI
CreativeMed (CELZ) Volatility Analysis | Q3 2025: Profit SurprisesBest Pick - Cổng thông tin điện tử tỉnh Lào Cai
PVH Technical Analysis & Price Forecast - Intellectia AI
VIVK Technical Analysis & Price Forecast - Intellectia AI
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
CreativeMed (CELZ) Stock Moving VWAP (Advances) 2026-04-18Rating Change - Newser
$ADA PE Ratio & Valuation, Is $ADA Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE) - Yahoo Finance
Creative Medical Technology Holdings Inc Stock (CELZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):